Esperion Appoints Robert E. Hoffman to Board of Directors

Core Insights - Esperion has appointed Robert E. Hoffman as an independent director and Chairperson of the Audit Committee, effective immediately and May 29, 2025, respectively [1][2] - Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors on June 1, 2025 [1] Company Developments - Robert E. Hoffman brings extensive experience in the biopharmaceutical sector, having held leadership roles in various companies, which is expected to benefit Esperion's commercialization efforts and pipeline expansion [2][4] - The company is focused on developing next-generation ATP citrate lyase inhibitors (ACLYi) to address unmet cardiometabolic needs [5][6] Leadership Background - Mr. Hoffman has previously served as President, CEO, and CFO of Kintara Therapeutics, and held senior financial roles at Heron Therapeutics and Arena Pharmaceuticals, contributing to his expertise in commercialization [2][4] - He is also involved with several other life sciences companies and has served on various financial committees, enhancing his leadership credentials [3][4] Company Overview - Esperion is a commercial-stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease [5] - The company aims to evolve into a leading global biopharmaceutical entity through commercial execution and international partnerships [6]